Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “High-Risk Melanoma”

254 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 254 results

Testing effectiveness (Phase 2)WithdrawnNCT04495010
What this trial is testing

Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Nivolumab or Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Observation Compared With Adjuvant Nivolumab in Treatment-Naive High-risk Melanoma Participants

Who this might be right for
Melanoma
Bristol-Myers Squibb
Very early researchEnded earlyNCT03454243
What this trial is testing

Oral Immunomodulatory Tyrosine Kinase Inhibitor in Patients With Locally Advanced or Metastatic Solid Tumors

Who this might be right for
Advanced or Metastatic Solid Tumors
Hoffmann-La Roche 1
Early research (Phase 1)Looking for participantsNCT07501117
What this trial is testing

Neoadjuvant Immunotherapy for Patients With High-risk Eye Melanoma

Who this might be right for
Uveal Melanoma
Inge Marie Svane 15
Not applicableEnded earlyNCT02439008
What this trial is testing

Early Biomarkers of Tumor Response in High Dose Hypofractionated Radiotherapy Word Package 3 : Immune Response

Who this might be right for
Carcinoma, HepatocellularColorectal NeoplasmsMelanoma+1 more
Centre Oscar Lambret 28
Testing effectiveness (Phase 2)Study completedNCT01266603
What this trial is testing

High-Dose Interleukin-2 (HDIL-2), Combined With recMAGE-A3 + AS15 ASCI

Who this might be right for
Melanoma
M.D. Anderson Cancer Center 44
Testing effectiveness (Phase 2)Study completedNCT03007823
What this trial is testing

High-activity Natural Killer Immunotherapy for Small Metastases of Melanoma

Who this might be right for
Melanoma
Fuda Cancer Hospital, Guangzhou 20
Very early researchLooking for participantsNCT06305962
What this trial is testing

177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors

Who this might be right for
PDL1 Gene MutationNon Small Cell Lung CancerSmall Cell Lung Cancer ( SCLC )+6 more
Radiopharm Theranostics, Ltd 30
Not applicableStudy completedNCT01905891
What this trial is testing

Nanocytology Test to Evaluate Skin Cancer in High Risk Patients

Who this might be right for
Actinic KeratosisSquamous Cell Carcinoma
Northwestern University 7
Testing effectiveness (Phase 2)Study completedNCT00019890
What this trial is testing

Vaccine Therapy in Treating Patients With High-Risk Stage III or Completely Resected Metastatic Melanoma

Who this might be right for
Stage IV MelanomaStage III MelanomaRecurrent Melanoma
National Cancer Institute (NCI)
Early research (Phase 1)Study completedNCT03538028
What this trial is testing

A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies

Who this might be right for
Cervical CancerMicrosatellite Instability (MSI)-High Endometrial CancerGastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ])+14 more
Incyte Biosciences International Sàrl 22
Testing effectiveness (Phase 2)Active Not RecruitingNCT03698019
What this trial is testing

Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma

Who this might be right for
Acral Lentiginous MelanomaClinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8+1 more
National Cancer Institute (NCI) 313
Testing effectiveness (Phase 2)Looking for participantsNCT06240143
What this trial is testing

Intradermal Ipilimumab and Nivolumab in High Risk Stage II Melanoma

Who this might be right for
Melanoma
The Netherlands Cancer Institute 96
Early research (Phase 1)Ended earlyNCT04458259
What this trial is testing

Study of PF-07265807 in Participants With Metastatic Solid Tumors.

Who this might be right for
Neoplasm Metastasis
Pfizer 88
Testing effectiveness (Phase 2)Ended earlyNCT00706992
What this trial is testing

Anti-MART-1 F5 Lymphocytes to Treat High-Risk Melanoma Patients

Who this might be right for
Melanoma
National Cancer Institute (NCI) 50
Testing effectiveness (Phase 2)Study completedNCT02178722
What this trial is testing

Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers

Who this might be right for
Microsatellite-instability (MSI) High Colorectal Cancer (CRC)Endometrial CancerHead and Neck Cancer+11 more
Incyte Corporation 444
Not applicableStudy completedNCT03653819
What this trial is testing

High Intensity Interval Training (HIIT) for Patients With Cancer-related Lymphedema in the Lower Limbs

Who this might be right for
Lymphedema of LegCancer of CervixCancer, Ovarian+3 more
Herlev and Gentofte Hospital 20
Not applicableEnded earlyNCT02900248
What this trial is testing

CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice

Who this might be right for
NeoplasmsLung NeoplasmsColon Neoplasms+22 more
CureOne 23
Testing effectiveness (Phase 2)Study completedNCT00928902
What this trial is testing

Trial for the Evaluation of the Effect of Systemic Low-dose Interleukin-2 (IL-2) on the Immunogenicity of a Vaccine Comprising Synthetic Melanoma Peptides Administered With Granulocyte-macrophage Colony-stimulating Factor (GM-CSF)-In-Adjuvant, in Patients With High Risk Melanoma

Who this might be right for
Melanoma
University of Virginia 41
Early research (Phase 1)Ended earlyNCT03991741
What this trial is testing

Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors

Who this might be right for
Metastatic MelanomaLocally Advanced Refractory/Recurrent MelanomaMetastatic Head and Neck Cancer+1 more
Gregory Daniels 3
Testing effectiveness (Phase 2)Looking for participantsNCT07410494
What this trial is testing

Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors

Who this might be right for
CancerBreast CancerNon-Small Cell Lung Cancer (NSCLC)+10 more
Essen Biotech 85
Next Page